Hutchmed (HCM) said Wednesday a phase 2 study of a combination therapy it co-developed with AstraZeneca (AZN) showed clinically meaningful and durable objective response rates in patients with a type of non-small cell lung cancer.

The study showed that the safety and tolerability of the combination of Tagrisso and Orpathys, co-developed by AstraZeneca and Hutchmed, was consistent with the known safety profiles of the combination, with no new safety signals identified, Hutchmed said.

Price: 18.81, Change: +0.01, Percent Change: +0.05